Clearpoint Neuro Stock Alpha and Beta Analysis
| CLPT Stock | USD 10.75 0.20 1.83% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Clearpoint Neuro. It also helps investors analyze the systematic and unsystematic risks associated with investing in Clearpoint Neuro over a specified time horizon. Remember, high Clearpoint Neuro's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Clearpoint Neuro's market risk premium analysis include:
Beta 2.2 | Alpha (0.01) | Risk 5.31 | Sharpe Ratio (0.07) | Expected Return (0.39) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Clearpoint |
Clearpoint Neuro Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Clearpoint Neuro market risk premium is the additional return an investor will receive from holding Clearpoint Neuro long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Clearpoint Neuro. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Clearpoint Neuro's performance over market.| α | -0.01 | β | 2.20 |
Clearpoint Neuro expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Clearpoint Neuro's Buy-and-hold return. Our buy-and-hold chart shows how Clearpoint Neuro performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Clearpoint Neuro Market Price Analysis
Market price analysis indicators help investors to evaluate how Clearpoint Neuro stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Clearpoint Neuro shares will generate the highest return on investment. By understating and applying Clearpoint Neuro stock market price indicators, traders can identify Clearpoint Neuro position entry and exit signals to maximize returns.
Clearpoint Neuro Return and Market Media
The median price of Clearpoint Neuro for the period between Wed, Jan 8, 2025 and Tue, Apr 8, 2025 is 15.12 with a coefficient of variation of 15.14. The daily time series for the period is distributed with a sample standard deviation of 2.31, arithmetic mean of 15.28, and mean deviation of 2.03. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Mazin Sabra of 65252 shares of Clearpoint Neuro subject to Rule 16b-3 | 01/10/2025 |
2 | Acquisition by Mazin Sabra of 6913 shares of Clearpoint Neuro subject to Rule 16b-3 | 01/17/2025 |
3 | How to Take Advantage of moves in - Stock Traders Daily | 01/29/2025 |
4 | Disposition of 908 shares by Stigall L. Jeremy of Clearpoint Neuro at 16.72 subject to Rule 16b-3 | 02/21/2025 |
5 | ClearPoint Neuro Inc Q4 2024 Everything You Need To Know Ahead Of Earnings | 02/25/2025 |
6 | ClearPoint Neuro Inc Reports Q4 Revenue of 7.8M, Missing Estimates Annual Revenue Reaches 31.4M | 02/26/2025 |
7 | Q4 2024 Clearpoint Neuro Inc Earnings Call Transcript | 02/27/2025 |
8 | Acquisition by Joseph Burnett of 132841 shares of Clearpoint Neuro subject to Rule 16b-3 | 03/03/2025 |
9 | FY2025 EPS Estimates for ClearPoint Neuro Lifted by B. Riley | 03/05/2025 |
10 | Disposition of 47407 shares by Joseph Burnett of Clearpoint Neuro subject to Rule 16b-3 | 03/06/2025 |
11 | Acquisition by Dalessandro Danilo of 18765 shares of Clearpoint Neuro subject to Rule 16b-3 | 03/10/2025 |
12 | Disposition of 4146 shares by Dalessandro Danilo of Clearpoint Neuro subject to Rule 16b-3 | 03/11/2025 |
13 | Disposition of 42414 shares by Joseph Burnett of Clearpoint Neuro subject to Rule 16b-3 | 03/12/2025 |
14 | Disposition of 2106 shares by Dalessandro Danilo of Clearpoint Neuro at 12.7 subject to Rule 16b-3 | 03/13/2025 |
15 | Disposition of 13050 shares by Mazin Sabra of Clearpoint Neuro subject to Rule 16b-3 | 03/14/2025 |
16 | ClearPoint Neuro Inc Shares Gap Down to 13.235 on Mar 25 | 03/25/2025 |
17 | Acquisition by Girin Pascal E R of 525 shares of Clearpoint Neuro at 11.89 subject to Rule 16b-3 | 04/01/2025 |
About Clearpoint Neuro Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Clearpoint or other stocks. Alpha measures the amount that position in Clearpoint Neuro has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Payables Turnover | 25.81 | 26.31 | 9.16 | 6.06 | Days Of Inventory On Hand | 483.7 | 279.23 | 204.19 | 394.35 |
Clearpoint Neuro Upcoming Company Events
As portrayed in its financial statements, the presentation of Clearpoint Neuro's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Clearpoint Neuro's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Clearpoint Neuro's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Clearpoint Neuro. Please utilize our Beneish M Score to check the likelihood of Clearpoint Neuro's management manipulating its earnings.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Clearpoint Neuro
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Clearpoint Stock Analysis
When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.